Equities analysts forecast that Ra Pharmaceuticals Inc (NASDAQ:RARX) will post earnings of ($0.50) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Ra Pharmaceuticals’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.53). Ra Pharmaceuticals reported earnings per share of ($0.51) during the same quarter last year, which would suggest a positive year-over-year growth rate of 2%. The business is scheduled to announce its next earnings report on Wednesday, November 6th.
On average, analysts expect that Ra Pharmaceuticals will report full-year earnings of ($1.97) per share for the current year, with EPS estimates ranging from ($2.08) to ($1.81). For the next year, analysts expect that the company will report earnings of ($2.53) per share, with EPS estimates ranging from ($2.90) to ($2.28). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.03).
In other Ra Pharmaceuticals news, insider Alonso Ricardo sold 2,857 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $23.72, for a total value of $67,768.04. Following the completion of the transaction, the insider now owns 11,428 shares of the company’s stock, valued at approximately $271,072.16. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Simon Read sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $22.25, for a total transaction of $222,500.00. Following the completion of the transaction, the insider now directly owns 8,521 shares of the company’s stock, valued at approximately $189,592.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,452 shares of company stock valued at $970,463. 4.30% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Prudential Financial Inc. grew its stake in Ra Pharmaceuticals by 0.5% in the 2nd quarter. Prudential Financial Inc. now owns 120,890 shares of the company’s stock worth $3,635,000 after buying an additional 640 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Ra Pharmaceuticals by 0.3% in the 1st quarter. JPMorgan Chase & Co. now owns 239,269 shares of the company’s stock worth $5,360,000 after buying an additional 678 shares in the last quarter. Legal & General Group Plc grew its stake in Ra Pharmaceuticals by 57.7% in the 4th quarter. Legal & General Group Plc now owns 3,063 shares of the company’s stock worth $56,000 after buying an additional 1,121 shares in the last quarter. Moody Aldrich Partners LLC grew its stake in Ra Pharmaceuticals by 2.8% in the 2nd quarter. Moody Aldrich Partners LLC now owns 41,039 shares of the company’s stock worth $1,234,000 after buying an additional 1,134 shares in the last quarter. Finally, Virginia Retirement Systems ET AL grew its stake in Ra Pharmaceuticals by 12.9% in the 2nd quarter. Virginia Retirement Systems ET AL now owns 10,500 shares of the company’s stock worth $316,000 after buying an additional 1,200 shares in the last quarter. 97.04% of the stock is owned by institutional investors and hedge funds.
Ra Pharmaceuticals stock traded up $0.70 during midday trading on Thursday, hitting $29.42. 376,400 shares of the stock were exchanged, compared to its average volume of 599,847. Ra Pharmaceuticals has a 52-week low of $10.02 and a 52-week high of $36.96. The business’s 50-day moving average price is $32.55 and its 200-day moving average price is $25.02. The company has a quick ratio of 15.30, a current ratio of 15.30 and a debt-to-equity ratio of 0.02.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.